Chemokines in Gestational Diabetes Mellitus

Hongying Liu; Aizhong Liu; Atipatsa C Kaminga; Judy McDonald; Shi Wu Wen; Xiongfeng Pan

doi:10.3389/fimmu.2022.705852

Chemokines in Gestational Diabetes Mellitus

Front Immunol. 2022 Feb 8:13:705852. doi: 10.3389/fimmu.2022.705852. eCollection 2022.

Authors

Hongying Liu¹, Aizhong Liu^{1

2}, Atipatsa C Kaminga^{1

3}, Judy McDonald⁴, Shi Wu Wen^{5

6}, Xiongfeng Pan¹

Affiliations

¹ Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China.
² Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
³ Department of Mathematics and Statistics, Mzuzu University, Mzuzu, Malawi.
⁴ McLaughlin Centre for Population Health Risk Assessment, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
⁵ OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
⁶ Department of Obstetrics and Gynaecology and School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, ON, Canada.

Abstract

Background: Studies investigating chemokines in gestational diabetes mellitus (GDM) have yielded mixed results. The purpose of this meta-analysis was to explore whether concentrations of chemokines in patients with GDM differed from that of the controls.

Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched Web of Science, Embase, Cochrane Library, and PubMed databases for articles, published in any language, on chemokines and GDM through August 1st, 2021. The difference in concentrations of chemokines between patients with GDM and controls was determined by a standardized mean difference (SMD) with a 95% confidence interval (CI), calculated in the meta-analysis of the eligible studies using a random-effects model with restricted maximum-likelihood estimator.

Results: Seventeen studies met the inclusion criteria for the meta-analysis. Altogether, they included nine different chemokines comparisons involving 5,158 participants (1,934 GDM patients and 3,224 controls). Results showed a significant increase of these chemokines (CCL2, CXCL1, CXCL8, CXCL9, and CXCL12) in the GDM patients compared with the controls. However, there was a significant decrease of the chemokines, CCL4, CCL11 and CXCL10, in the GDM patients compared with the controls. Moreover, subgroup analysis revealed a potential role of chemokines as biomarkers in relation to laboratory detection (different sample type and assay methods) and clinical characteristics of GDM patients (ethnicity and body mass index).

Conclusion: GDM is associated with several chemokines (CCL2, CCL4, CCL11, CXCL1, CXCL8, CXCL9, CXCL10 and CXCL12). Therefore, consideration of these chemokines as potential targets or biomarkers in the pathophysiology of GDM development is necessary. Notably, the information of subgroup analysis underscores the importance of exploring putative mechanisms underlying this association, in order to develop new individualized clinical and therapeutic strategies.

Keywords: chemokines; gestational diabetes mellitus; immune microenvironment; inflammatory; meta-analysis.

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

MeSH terms

Biomarkers / metabolism
Chemokines / metabolism*
Diabetes, Gestational / immunology*
Female
Humans
Pregnancy

Substances

Biomarkers
Chemokines